Evidence map›Paper›PMID 34389029›Full record

ArticleBioData mining2021

Probability calibration-based prediction of recurrence rate in patients with diffuse large B-cell lymphoma.

Shuanglong Fan, Zhiqiang Zhao, Yanbo Zhang, Hongmei Yu, Chuchu Zheng, Xueqian Huang, Zhenhuan Yang, Meng Xing, Qing Lu, Yanhong Luo

Abstract read
In one paragraph

Article in BioData mining, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuanglong FanDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Zhiqiang ZhaoDepartment of Hematology, Shanxi Cancer Hospital, Taiyuan, China.
Yanbo ZhangDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Hongmei YuDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Chuchu ZhengDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Xueqian HuangDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Zhenhuan YangDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Meng XingDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China.
Qing LuDepartment of Epidemiology and Biostatistics, Michigan State University, East Lansing, USA. lucienq@hotmail.com.
Yanhong LuoDepartment of Health Statistics, School of Public Health, Shanxi Medical University, Taiyuan, China. sxmulyh@126.com.ORCID http://orcid.org/0000-0002-0943-4169

Funding

national natural science foundation of china 81502897national natural science foundation of china 81973154
6 · The paper itself

Abstract

backgroundAlthough many patients receive good prognoses with standard therapy, 30-50% of diffuse large B-cell lymphoma (DLBCL) cases may relapse after treatment. Statistical or computational intelligent models are powerful tools for assessing prognoses; however, many cannot generate accurate risk (probability) estimates. Thus, probability calibration-based versions of traditional machine learning algorithms are developed in this paper to predict the risk of relapse in patients with DLBCL.

methodsFive machine learning algorithms were assessed, namely, naïve Bayes (NB), logistic regression (LR), random forest (RF), support vector machine (SVM) and feedforward neural network (FFNN), and three methods were used to develop probability calibration-based versions of each of the above algorithms, namely, Platt scaling (Platt), isotonic regression (IsoReg) and shape-restricted polynomial regression (RPR). Performance comparisons were based on the average results of the stratified hold-out test, which was repeated 500 times. We used the AUC to evaluate the discrimination ability (i.e., classification ability) of the model and assessed the model calibration (i.e., risk prediction accuracy) using the H-L goodness-of-fit test, ECE, MCE and BS.

resultsSex, stage, IPI, KPS, GCB, CD10 and rituximab were significant factors predicting the 3-year recurrence rate of patients with DLBCL. For the 5 uncalibrated algorithms, the LR (ECE = 8.517, MCE = 20.100, BS = 0.188) and FFNN (ECE = 8.238, MCE = 20.150, BS = 0.184) models were well-calibrated. The errors of the initial risk estimate of the NB (ECE = 15.711, MCE = 34.350, BS = 0.212), RF (ECE = 12.740, MCE = 27.200, BS = 0.201) and SVM (ECE = 9.872, MCE = 23.800, BS = 0.194) models were large. With probability calibration, the biased NB, RF and SVM models were well-corrected. The calibration errors of the LR and FFNN models were not further improved regardless of the probability calibration method. Among the 3 calibration methods, RPR achieved the best calibration for both the RF and SVM models. The power of IsoReg was not obvious for the NB, RF or SVM models.

conclusionsAlthough these algorithms all have good classification ability, several cannot generate accurate risk estimates. Probability calibration is an effective method of improving the accuracy of these poorly calibrated algorithms. Our risk model of DLBCL demonstrates good discrimination and calibration ability and has the potential to help clinicians make optimal therapeutic decisions to achieve precision medicine.

Indexed as

Discrimination and calibrationDLBCLProbability calibrationRisk prediction

Identifiers

PMID34389029
PMCPMC8362168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.